Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03836209
Other study ID # PrE0905
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 6, 2019
Est. completion date December 2024

Study information

Verified date February 2024
Source PrECOG, LLC.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation. Gilteritinib, is an oral drug that works by stopping the leukemia cells from making the FLT3 protein. This may help stop the leukemia cells from growing faster and thus may help make chemotherapy more effective. Gilteritinib has been approved by the Food and Drug Administration (FDA) for patients who have relapsed or refractory AML with a FLT3 mutation but is not approved by the FDA for newly diagnosed FLT3 AML, and its use in this setting is considered investigational. Midostaurin is an oral drug that works by blocking several proteins on cancer cells, including FLT3 that can help leukemia cells grow. Blocking this pathway can cause death to the leukemic cells. Midostaurin is approved by the FDA for the treatment of FLT3 AML. The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving combination chemotherapy for FLT3 AML.


Description:

Approximately one third of patients with AML have a particular change in their leukemia cells (called a mutation) in a gene called FLT3. The presence of a FLT3 mutation can be used to direct treatment options. This is an open-label phase II study. Patients will receive standard chemotherapy of daunorubicin and cytarabine during Induction and high-dose cytarabine during Consolidation. Patients will be randomized to gilteritinib or midostaurin. After approximately 90 patient's complete treatment, a review of the effectiveness of gliteritinib compared to midostaurin will be done. If gilteritinib is not as effective as midostaurin, the study may be stopped. Bone marrow aspirate and biopsy will be done on Day 21 after start of Induction and after Induction to assess response. Patients with a complete response may proceed to consolidation chemotherapy. Another bone marrow aspirate and biopsy will be done after the first cycle of consolidation is complete. Mandatory prescreening bone marrow and/or blood samples are required for FLT3 testing. Any left-over samples will be requested for future research (optional). Mandatory bone marrow samples for research are required after Induction and if patient receives Consolidation, after the first cycle of Consolidation.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 181
Est. completion date December 2024
Est. primary completion date October 17, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Registration Criteria: - Any patient undergoing bone marrow biopsy with suspicion of or known diagnosis of acute myeloid leukemia (AML) will be asked to sign a Prescreening Consent to allow for centralized testing of bone marrow/peripheral blood samples. Randomization Eligibility Criteria: - Patient must have previously untreated FLT3 mutated Non M3 AML (FLT3-TKD or FLT3-ITD allowed). ° Standard of care induction 7+3 chemotherapy may start prior to randomization using same regimen and doses as defined in the protocol while awaiting prescreening test results. - Patient must have had no prior systemic therapy for AML, except as noted below: - Hydroxyurea and emergent leukapheresis or preemptive treatment with retinoic acid prior to exclusion of Acute Promyelocytic Leukemia (APL) allowed. - Prior therapy for myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN) (e.g., thalidomide or lenalidomide, interferon, jakafi, cytokines, 5-azacytidine or decitabine, histone deacetylase inhibitors). - Initiation of standard of care 7+3 induction chemotherapy using same regimen and doses as defined in protocol while awaiting prescreening test results - Patient may not have received hypomethylating agent within 21 days. - Patient may not have M3 AML. - Patient may not have AML with known Core Binding Factor -t(8;21), inv(16), t(16;16). - Patient may not have known active Central Nervous System (CNS) leukemia. ° Prophylaxis with intrathecal chemotherapy is allowed prior to or during induction/consolidation. - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3. - Patient must be age = 18 years to = 70 years. - Patient must be able to understand and willing to sign Institutional Review Board (IRB)-approved informed consent. - Patient must be willing to provide mandatory bone marrow and blood samples for research. - Patient must have adequate organ function as measured by the following criteria, obtained = 48 hours prior to randomization except ECG and left ventricular ejection fraction (LVEF) which can be done = 2 weeks prior to randomization: - Serum creatinine = 1.5x institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) >40 mL/min as measured by Cockcroft-Gault formula. - Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) = 3x ULN, unless secondary to leukemia. - Serum total or direct bilirubin <2 mg/dL, unless due to Gilbert's, hemolysis or leukemic infiltration. - Fridericia-Corrected QT Interval (QTcF) interval = 500 msec (using Friderica's correction). - Left Ventricular Ejection Fraction >45%. - The patient may not be known to have hypokalemia and/or hypomagnesemia that does not respond to supplementation. - A female patient is eligible to participate if she is not pregnant and at least one of the following conditions apply: - Not a woman of childbearing potential (WOCBP) OR - WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 180 days after the final study drug administration. - Female patient must agree not to breastfeed or donate ova starting at treatment and throughout the study period, and for at least 180 days after the final study drug administration. - A male patient must agree not to donate sperm starting at treatment and throughout the study period, and for at least 120 days after the final study drug administration. - A male patient with female partner(s) of child-bearing potential must agree to use contraception during the treatment period, and for at least 120 days after the final study drug administration. - Male patient with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the treatment period, and for at least 120 days after the final study drug administration. - Patient may not have another malignancy that could interfere with the evaluation of safety or efficacy of this combination. - Patient may not have a history of Long QT Syndrome. - Patient may not have evidence of uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or congestive heart failure (CHF) New York Heart Association (NYHA) Class 3 or 4. Patient may also not have a history of CHF NYHA Class 3 or 4 in the past, unless a prescreening echocardiogram (ECHO) or multigated acquisition scan (MUGA) performed within 2 weeks prior to study entry with results of left ventricular ejection fraction >45%. - Patient may not have had major surgery or radiation therapy within 4 weeks of registration. - Patient may not require treatment with concomitant drugs that are strong inducers of CYP3A and P-gp. - Patient with a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligible. - Patient with known gastrointestinal (GI) disease or prior GI procedure that could interfere with the oral absorption or tolerance of gilteritinib or midostaurin including difficulty swallowing are not eligible. - Patient with any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of the treatment according to the protocol are not eligible. - Patient may not participate in any other therapeutic clinical trials, including those with other investigational agents not included in this trial during treatment on this study without prior approval from PrECOG.

Study Design


Intervention

Drug:
Gilteritinib
Induction: 120 mg orally daily x 14 days starting on day 8 Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)
Midostaurin
Induction: 50 mg orally twice daily x 14 days beginning on day 8 Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)
Daunorubicin
First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3 Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3
Cytarabine
Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1 Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1 Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age = 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles

Locations

Country Name City State
United States St. Joseph's Mercy Hospital Ann Arbor Michigan
United States Augusta University Medical Center Augusta Georgia
United States Johns Hopkins University Baltimore Maryland
United States Massachusetts General Hospital Boston Massachusetts
United States Tufts Medical Center Boston Massachusetts
United States Northwestern University Feinberg School of Medicine Chicago Illinois
United States University of Chicago Medical Center Chicago Illinois
United States University of Cincinnati Medical Center Cincinnati Ohio
United States University Hospitals Cleveland Medical Center Cleveland Ohio
United States University of California, San Francisco-Fresno (University Oncology Associates) Clovis California
United States Geisinger Medical Center Danville Pennsylvania
United States East Carolina University Greenville North Carolina
United States Penn State Milton S. Hershey Medical Center Hershey Pennsylvania
United States Franciscan Health Indianapolis Indianapolis Indiana
United States Mayo Clinic- Jacksonville, FL Jacksonville Florida
United States Northwell Health Lake Success New York
United States University of Kentucky Markey Cancer Center Lexington Kentucky
United States UCLA Los Angeles California
United States University of Wisconsin Clinical Science Center Madison Wisconsin
United States Marshfield Medical Center Marshfield Wisconsin
United States Medical College of Wisconsin Milwaukee Wisconsin
United States West Virginia University Morgantown West Virginia
United States Atlantic Health Systems/Morristown Medical Center Morristown New Jersey
United States Vanderbilt University Nashville Tennessee
United States Ochsner Clinic Foundation New Orleans Louisiana
United States Memorial Sloan Kettering Cancer Center New York New York
United States Mount Sinai New York New York
United States Weill Cornell Medicine New York Presbyterian Hospital New York New York
United States Kaiser Permanente Oakland Oakland California
United States University of Oklahoma Stephenson Cancer Center Oklahoma City Oklahoma
United States University of Nebraska Medical Center Omaha Nebraska
United States UC Irvine Health Orange California
United States Thomas Jefferson University Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Mayo Clinic- Rochester, MN Rochester Minnesota
United States University of Rochester Medical Center Rochester New York
United States Kaiser Permanente Roseville Roseville California
United States LDS Hospital Salt Lake City Utah
United States Kaiser Permanente Santa Clara Santa Clara California
United States HonorHealth Research Institute Scottsdale Arizona
United States MultiCare Spokane Washington
United States SUNY Upstate Medical University Syracuse New York
United States UW Cancer Center at ProHealth Care Waukesha Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
PrECOG, LLC. Astellas Pharma Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary FLT3 Mutation Negative Composite Complete Response (CRc) [includes Complete Response (CR) or CR with incomplete hematologic recovery (CRi)] at end of Induction CRc evaluated by polymerase chain reaction (PCR) at the end of Induction 3 months
Secondary FLT3 mutation negative Complete Response (CR) rate at end of Induction CR evaluated by FLT3 testing after Induction 3 months
Secondary Minimal Residual Disease (MRD)- CRc rate at end of Induction MRD- CRc evaluated by flow cytometry after Induction 3 months
Secondary CRc (CR or CRi) rate at end of Induction CRc assessed in accordance with 2017 European LeukemiaNet (ELN) 3 months
Secondary Event Free Survival (EFS) EFS assessed in accordance with 2017 ELN 68 months
Secondary Overall Survival (OS) OS assessed in accordance with 2017 ELN 68 months
Secondary Number of participants treatment-related adverse events on Arm A (gilteritinib) as assessed by CTCAE v5.0 Number of participants with abnormal laboratory values and/or adverse events 10 months
Secondary Number of participants treatment-related adverse events on Arm B (midostaurin) as assessed by CTCAE v5.0 Number of participants with abnormal laboratory values and/or adverse events 10 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2